Microbial therapies, such as prebiotics and probiotics, show potential in patients with nonalcoholic fatty liver disease, yielding reductions in body mass index, hepatic enzymes, serum cholesterol and triglycerides, a study has shown.
Coeliac disease patients have a threefold risk of nonalcoholic fatty liver disease (NAFLD) despite adherence to a gluten-free diet, a study has found. This risk is especially higher in the lean population.
Supplementation with omega-3 long-chain polyunsaturated fatty acids appears beneficial to patients with nonalcoholic fatty liver disease (NAFLD), producing significant improvements in liver fat content, steatosis score and several cardiometabolic risk factors, according to a systematic review and meta-analysis.
In Asian patients with nonalcoholic fatty liver disease, more severe liver disease is associated with factors such as older age, obesity, diabetes, dyslipidaemia, higher alanine transaminase and aspartate transaminase levels, and lower platelet count, according to a team of investigators.
Multiparametric magnetic resonance imaging (MRI) accurately identifies patients with nonalcoholic fatty liver disease (NAFLD), stratifying between nonalcoholic steatohepatitis and simple steatosis as well as between low and high risk of progressive liver disease, according to a study. However, the approach appears to be inferior for staging of fibrosis.
The apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib appears to have favourable effects on liver fibrosis in patients with nonalcoholic steatohepatitis and stage II to III fibrosis, according to the results of a phase II exploratory trial.
The Asian Pacific Digestive Week (APDW) 2017, to be held in Hong Kong on 23–26 September, will examine key issues in and the future of digestive disease management in the Asia-Pacific region. Professor Justin Wu of the Chinese University of Hong Kong (CUHK), Congress President of APDW 2017 and President of the Hong Kong Society of Gastroenterology, talks to MIMS Doctor about challenges the region is facing and shares highlights of the upcoming congress.
Silymarin does not appear to be significantly better than placebo in reducing disease activity by 30 percent or more in patients with nonalcoholic steatohepatitis (NASH), according to the results of a trial.